ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0236

Impact of Socioeconomic Status on Infection-Related Hospitalization Risk in Patients with Systemic Autoimmune Diseases

Infection-related Rheumatic Disease Poster

10:30AM-12:30PM: Abstract Number: 0720

Impact of Systemic Vasculitides on Sexual Function: An Overlooked Aspect of Patient Care

Vasculitis – ANCA-Associated Poster I

10:30AM-12:30PM: Abstract Number: 0626

Impact of the Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) Patient Reported Outcome (PRO) in Systemic Lupus Erythematosus Patients from the Almenara Lupus Cohort

SLE – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0349

Impact of the Stanford University Chronic Pain Self-Management Education Program on Pain Severity, Pain Self-Efficacy, and Pain Disability in a Population with a High Prevalence of Arthritis

Patient Education/Community Programs Poster – ARP

10:30AM-12:30PM: Abstract Number: 0051

Impact of Tight Junction Proteins on Inflammatory Processes and Microbial Imbalance in Rheumatoid Arthritis

RA – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0472

Impaired Cardiac Function in Contemporary Rheumatoid Arthritis Patients: A Comparative Pilot Study with Cardiovascular Magnetic Resonance-derived Strain Analysis

RA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0046

Impaired Neutrophil Extracellular Trap (NET) Degradation in Rheumatoid Arthritis (RA) and Pre-clinical RA Is Mediated by Anti-NET Antibodies

RA – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0355

Improvements in Patient-Reported Outcomes After Treatment with SEL-212 in Adults with Refractory Gout: Results from Two Randomized Phase 3 Trials

Patient Outcomes, Preferences, & Attitudes Poster I

10:30AM-12:30PM: Abstract Number: 0490

Improvements in Peri-fracture Care in Rheumatoid Arthritis (RA) Have Offset Increased Mortality

RA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0184

Improving Age Disparities in Contraceptive Counseling in Women with Lupus: A Quality Improvement Initiative

Healthcare Disparities in Rheumatology Poster I

10:30AM-12:30PM: Abstract Number: 0418

Improving Documentation of Contraception and Pregnancy Intention in Rheumatology Practice

Reproductive Issues in Rheumatic Disorders Poster

10:30AM-12:30PM: Abstract Number: 0377

Improving Self-Management Support in Patients with Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0718

Incidence and Patient Profile Changes in ANCA-Associated Vasculitis Following the SARS-CoV-2 Pandemic

Vasculitis – ANCA-Associated Poster I

10:30AM-12:30PM: Abstract Number: 0724

Incidence of ANCA-Associated Vasculitis in a Northern Spanish Health Region Between 2000-2023: A Populatio-based Study

Vasculitis – ANCA-Associated Poster I

10:30AM-12:30PM: Abstract Number: 0218

Incidental Findings on Whole Body 18F-FDG PET/CT in a Rheumatoid Arthritis Clinical Trial Population

Imaging of Rheumatic Diseases Poster I: Inflammatory Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].